ContraFect Corporation (CFRX) Analysts See $-0.10 EPS

February 24, 2018 - By reb123z

 ContraFect Corporation (CFRX) Analysts See $ 0.10 EPS

Analysts expect ContraFect Corporation (NASDAQ:CFRX) to report $-0.10 EPS on March, 21.They anticipate $0.05 EPS change or 33.33 % from last quarter’s $-0.15 EPS. After having $0.04 EPS previously, ContraFect Corporation’s analysts see -350.00 % EPS growth. The stock increased 1.23% or $0.02 during the last trading session, reaching $1.65. About 98,505 shares traded. ContraFect Corporation (NASDAQ:CFRX) has declined 42.92% since February 24, 2017 and is downtrending. It has underperformed by 59.62% the S&P500.

ContraFect Corporation (NASDAQ:CFRX) Ratings Coverage

Among 3 analysts covering ContraFect (NASDAQ:CFRX), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. ContraFect had 5 analyst reports since December 31, 2015 according to SRatingsIntel. The firm has “Outperform” rating by William Blair given on Wednesday, September 28. The firm has “Buy” rating given on Friday, July 22 by Maxim Group. Roth Capital downgraded it to “Neutral” rating and $3.30 target in Tuesday, May 10 report. Maxim Group maintained ContraFect Corporation (NASDAQ:CFRX) rating on Thursday, December 31. Maxim Group has “Buy” rating and $9 target.

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. The company has market cap of $121.53 million. The Company’s lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of human influenza. It currently has negative earnings. The firm has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza.

Another recent and important ContraFect Corporation (NASDAQ:CFRX) news was published by which published an article titled: “ContraFect: Why Hasn’t Anyone Else Done This Already?” on July 27, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: